Anti-Diabetes Drugs - Puerto Rico

Puerto Rico

In Puerto Rico, the revenue in the Anti-Diabetes Drugs market is forecasted to reach US$27.81m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 6.90%, leading to a market volume of US$38.83m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, amounting to US$37,840.00m in 2024.
The demand for anti-diabetes drugs is on the rise in Puerto Rico due to the increasing prevalence of diabetes in the population.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Puerto Rico has been experiencing steady growth over the years.

Customer preferences: Puerto Rico has a high prevalence of diabetes, which has led to an increase in demand for anti-diabetes drugs. Patients in Puerto Rico prefer drugs that are effective, affordable, and have minimal side effects. Additionally, there is a growing preference for combination therapies that offer multiple benefits.

Trends in the market: The market for anti-diabetes drugs in Puerto Rico is dominated by big pharmaceutical companies that offer a wide range of products. The trend in the market is towards the development of more innovative drugs that offer better outcomes for patients. There is also a growing trend towards the use of biosimilars, which are cheaper alternatives to branded drugs. The market is expected to continue growing due to the increasing prevalence of diabetes in the country.

Local special circumstances: Puerto Rico is a US territory, which means that the market is regulated by the FDA. This has led to a high level of quality control and safety in the market. Additionally, the island has a large pharmaceutical manufacturing industry, which has led to the availability of a wide range of drugs at affordable prices.

Underlying macroeconomic factors: Puerto Rico has been facing economic challenges in recent years, which has led to a decrease in healthcare spending. This has led to a shift towards the use of more affordable drugs, including generics and biosimilars. However, the government has been taking steps to improve healthcare access and this is expected to lead to an increase in demand for anti-diabetes drugs in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.